Recent Updates
Recently added Catalysts

Nu-3

Phase 2

Diabetic Foot Infection | Small molecule | Metabolic |Lakewood-Amedex Biotherapeutics Inc.|Last Updated: May 4, 2026

Target and mechanism

ModalitySmall molecule

Also known as 5% Nu-3 gel, 5% Nu-3, 10% Nu-3 gel, 10% Nu-3, Antimicrobial agent

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

Clinical trial landscape

Nu-3 · 2 trials · 2 indications

Phase 2 2
NCT07565506Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFUDiabetic Foot Ulcers (DFUs)
NOT YET_RECRUITING24 Analytics
NCT06020235Nu-3 Gel for Infected Diabetic Foot UlcersDiabetic Foot Infection
NOT YET_RECRUITING60 Analytics
PHASE2NOT YET_RECRUITING
Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU
Diabetic Foot Ulcers (DFUs)Unlock trial analytics
PHASE2NOT YET_RECRUITING
Nu-3 Gel for Infected Diabetic Foot Ulcers
Diabetic Foot InfectionUnlock trial analytics

Study Endpoints

Primary Endpoints

Primary Efficacy Outcome
From enrollment to the end of day 7 and at the end of treatment at day 14

The rate reduction in CFUs by ≥ 2 logs per pathogen, which is identified as typical and highly suspicious for being the cause of the infection compared to baseline.

Primary Safety Outcome
From enrollment to the end of study participation at 4 weeks

Number of AEs overall and those assessed by the investigators as possibly, probably, and definitely related to the study drug as well as the number of SAEs per patient and cohort.

Safety
Day 0 to Day 28

Number of AEs overall and those assessed by the investigators as possibly, probably, and definitely related to the study drug; number of SAEs per patient and cohort

Efficacy
Day 0 to Day 14

The rate of reduction in CFUs by \>=2 logs per pathogen identified as typical and highly suspicious for being the cause of the infection, in each treatment group compared to placebo group at Day 7 compared to Day 0, and Day 14 compared to Day 0.

Secondary Endpoints

Treatment success by dose
From enrollment to the end of treatment at 2 weeks
Treatment failures by dose
From enrollment to the end of treatment at 2 weeks
Secondary safety outcomes
From enrollment to 7 days of treatment, end of treatment at 2 weeks, and end of study participation in the study at 4 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
2.5mg doseEXPERIMENTALTwice daily application for 14 days
5mg doseEXPERIMENTALTwice daily application for 14 days
10mg doseEXPERIMENTALTwice daily application for 14 days
5% Nu-3 gel once dailyEXPERIMENTALThe 5% Nu-3 gel is applied once per day and placebo is applied once per day.
5% Nu-3 gel twice dailyEXPERIMENTALThe 5% Nu-3 gel is applied twice per day.
10% Nu-3 gel once dailyEXPERIMENTALThe 10% Nu-3 gel is applied once per day and placebo is applied once per day.
10% Nu-3 gel twice dailyEXPERIMENTALThe 10% Nu-3 gel is applied twice per day.
PlaceboPLACEBO_COMPARATORThe placebo is applied twice per day.

Interventions

NameTypeDescription
Antimicrobial agentDRUGTopical antimicrobial gel application twice a day for 2 weeks
5% Nu-3 gelDRUGThe gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
10% Nu-3 gelDRUGThe gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
PlaceboDRUGPlacebo gel is either applied once per day or twice per day to the infected ulcer.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: 1. Male and female subjects ≥18 years of age. 2. Voluntary written informed consent, including information about the provisions of the Health Insurance Portability and accountability act (HIPAA) as applicable. 3. Non-hospitalized ambulatory subjects diagnosed with diabetes melli...

Unlock Eligibility Criteria